STANDARD TREATMENT WITH BEVACIZUMAB AS TARGETED THERAPY IN CERVICAL CANCER

被引：0
|
作者：
Enriquez-Aceves, Isabel [1 ]
Galicia-Carmona, Tatiana [2 ,3 ]
Coronel-Martinez, Jaime A. [2 ,3 ]
Espinosa-Romero, Raquel [3 ]
Calderillo-Ruiz, German [3 ]
Cortes-Esteban, Patricia [4 ]
Cetina-Perez, Lucely [2 ,3 ]
机构：
[1] Hosp Inst Seguridad & Serv Sociales Trabajadores, Dept Med Oncol, Leon, Gto, Mexico
[2] Inst Nacl Cancerol, Dept Clin Res, Mexico City, DF, Mexico
[3] Inst Nacl Cancerol, Dept Med Oncol, Mexico City, DF, Mexico
[4] Ctr Med Nacl 20 Noviembre, Dept Med Oncol, Mexico City, DF, Mexico
来源：
REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION | 2020年 / 72卷 / 04期
关键词：
Bevacizumab; Cervical; Cancer; Metastatic antiangiogenic; PHASE-II TRIAL; SQUAMOUS-CELL-CARCINOMA; COMBINATION THERAPY; 3RD-LINE TREATMENT; OPEN-LABEL; RECURRENT; PERSISTENT; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL;
D O I：
10.24875/RIC.20000061
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Metastatic, recurrent, or persistent disease in cervical cancer has a poor prognosis. Historically, this group of patients has had limited treatment options, even with the best cytotoxic treatments (platinum-based chemotherapy [CT] doublets). Therefore, investigating new medications that help improve the patient's quality of life and survival has been essential. Angiogenesis has been shown to play a critical role in tumor cell growth and survival. Bevacizumab is a recombinant humanized monoclonal G1 immunoglobulin targeted against vascular endothelial growth factor. The combination of CT and bevacizumab is associated with an increase in overall survival as well as in progression-free survival and response rates.
引用
收藏
页码：213 / 218
页数：6
相关论文
共 50 条
  • [21] Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer
    He, Ying
    Wang, Jing
    Xie, Shuangshuang
    Xue, Qianlong
    FRONTIERS IN SURGERY, 2022, 9
  • [22] A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer
    Kitagawa, Ryo
    Katsumata, Noriyuki
    Ando, Masashi
    Shimizu, Chikako
    Fujiwara, Yasuhiro
    Yoshikawa, Hiroyuki
    Satoh, Toyomi
    Nakanishi, Toru
    Ushijima, Kimio
    Kamura, Toshiharu
    GYNECOLOGIC ONCOLOGY, 2012, 125 (02) : 307 - 311
  • [23] Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer The BC Cancer Experience
    Tinker, Anna V.
    Fiorino, Leathia
    O'Dwyer, Helena
    Kumar, Aalok
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (08) : 1592 - 1599
  • [24] Cervical cancer therapy: current, future and anti-angiogensis targeted treatment
    Willmott, Lyndsay J.
    Monk, Bradley J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (07) : 895 - 903
  • [25] Imaging on Lung Cancer and Treatment with Targeted Therapy
    Shroff, Girish S.
    Benveniste, Marcelo F.
    de Groot, Patricia M.
    Carter, Brett W.
    Wu, Carol C.
    Viswanathan, Chitra
    Truong, Mylene T.
    SEMINARS IN ULTRASOUND CT AND MRI, 2018, 39 (03) : 308 - 313
  • [26] Immunotherapy and targeted therapy for cervical cancer: an update
    Menderes, Gulden
    Black, Jonathan
    Schwab, Carlton L.
    Santin, Alessandro D.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (01) : 83 - 98
  • [27] Targeted therapy of ovarian cancer
    Volkmer, Anne Kathrin
    Fehm, Tanja
    Meier, Werner
    Ruckhaberle, Eugen
    GYNAKOLOGE, 2021, 54 (01): : 55 - 63
  • [28] The Incorporation of Immunotherapy and Targeted Therapy Into Chemoradiation for Cervical Cancer: A Focused Review
    Odiase, Otasowie
    Noah-Vermillion, Lindsay
    Simone, Brittany A.
    Aridgides, Paul D.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [29] Targeted therapy in locally and metastatic recurrent cervical cancers
    Geiss, Romain
    Rouge, Thibault De La Matte
    Dubot, Coraline
    Leary, Alexandra
    Lhomme, Catherine
    Pautier, Patricia
    Scholl, Suzy
    Rodrigues, Manuel Jorge
    BULLETIN DU CANCER, 2014, 101 (7-8) : 748 - 755
  • [30] Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
    Klavans, Madison R.
    Erickson, Sarah H.
    Modesitt, Susan C.
    GYNECOLOGIC ONCOLOGY REPORTS, 2020, 34
12345